Danaher Corp

Posted on | by Leon Hinde | Leave a Comment on Danaher Corp

Danaher Corporation Common is under Algo Engine buy conditions.

Share Price Correction & Valuation Opportunity

  • Deep Valuation Discount: DHR has undergone a significant correction, falling roughly 30% year-to-date to trade near its 52-week low of around $161–$163. This pullback has compressed its forward P/E ratio to an attractive 19x–23x range (well below its historical averages) and puts the stock at a steep discount to its estimated DCF intrinsic value of ~$227 per share.

1–3 Year Earnings Growth Outlook

Upward EPS Momentum & Strategic M&A: Following strong Q1 execution, management raised its full-year 2026 adjusted EPS guidance to $8.35–$8.55. Looking out 2 to 3 years, earnings will be further amplified by the integration of Masimo Corporation (a $9.9B acquisition expected to close in H2 2026), where Danaher plans to rapidly scale margins using its signature Danaher Business System (DBS).

Bioprocessing Cycle Rebound: Danaher is in the early stages of a multi-year bioprocessing equipment reinvestment cycle. In Q1 2026, equipment orders surged over 30% year-over-year; as these orders convert to revenue over the next 12 to 36 months, they will drive highly profitable, recurring consumables sales.

Consensus 3-Year Outlook

Steady Compounder: Wall Street consensus model forecasts project a long-term normalized annual revenue growth rate of ~5.5% over the next 1 to 3 years as the life sciences sector fully transitions out of its post-pandemic digestion phase

James Hardie Industries

Posted on | by Leon Hinde | Leave a Comment on James Hardie Industries

James Hardie Industries is under Algo Engine buy conditions.

Full-Year FY26 Results – The building materials giant reported its FY26 full-year results this morning, beating underlying earnings guidance despite facing a challenging global macro environment.

Dividends: No dividend was declared or paid for the year.

Full-Year Net Sales: US$4.84 billion, up 25% (boosted by the AZEK acquisition). Siding & Trim organic sales decreased 2%. Statutory Net Profit: US$104.0 million, down 75% year-on-year, weighed down by restructuring charges, asbestos compensation claims, and AZEK integration costs. Adjusted EBITDA: US$1.27 billion, up 17%, exceeding the company’s prior guidance.

Outlook: For FY27, management targets pro forma Adjusted EBITDA growth of 4% to 8% (US$1.45–$1.50 billion) and free cash flow of at least US$500 million.

Inner Circle

Posted on | by Leon Hinde | Leave a Comment on Inner Circle

Pfizer, Inc. Common is under Algo Engine buy conditions.

reported its Q1 2026 financial results on May 5, 2026, delivering a beat on both top and bottom lines as the company continues its transition away from peak pandemic-era revenues. Operational revenue from “launched and acquired products” surged 22%, driven by strong performance in the oncology and specialty care portfolios.

Q1 2026 Earnings Summary

  • Adjusted EPS: $0.75 (Beat consensus estimate of $0.72 by $0.03).
  • Total Revenue: $14.45 billion (Beat estimate of ~$13.84 billion; up 5% year-over-year).
  • Operational Growth: 2% (Excluding COVID-19 products, operational revenue grew 7%).
  • GAAP EPS: $0.47 (Down from $0.52 in Q1 2025).

      • Full-Year Revenue: $59.5 billion – $62.5 billion.
      • Adjusted Diluted EPS: $2.80 – $3.00.